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Abstract: The sessions during the 2 days of the Asthma Summit
focused largely on some specific aspects of the current European and
U.S. guidelines for managing asthma. By way of summary, the
faculty addressed the question of what they thought the guidelines
missed, starting with consideration of those aspects of their own
practice management that they believed are not clearly discussed in
current guidelines.
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ASTHMA SUMMIT 2009: WHAT THE
GUIDELINES HAVE MISSED, A GENERAL
DISCUSSION OF THE FACULTY
Dr. Calhoun: For me, an issue is that the guidelines don’tdiscuss the concept of personalized therapy—the notion
of individual phenotypes based on genetic, genomic, func-
tional genomic, or proteomic or even clinical demographic
predictors. Do the rest of you think that personalized medi-
cine is important, or is it simply the newest catch phrase?
Dr. Busse: I think this was addressed in some of the
later sections of the Expert Panel Report 3 (EPR-3) and also
in an accompanying editorial in Journal of Allergy. Person-
alized medicine is emerging, and we’ve talked about it here
with regard to phenotypes—including even different pheno-
types for exercise-provoked bronchospasm. The unifying
idea is that by looking at specific patterns of symptoms and
then patterns of responses, we’ll have a far more educated
guess as to the best therapeutic approach. We’re not yet ready
for genotyping, which is a far more advanced approach that
may be available down the road.
Dr. Luskin: I think we need to take that with caution
because personalized medicine depends upon who’s practic-
ing it. One of the reasons the Guidelines Committee was set
up in the first place in 1989 was because there was so much
variability of practice, and the variability was associated with
poor outcomes and high cost. So while I, like any one of you
in this room, would like to be practicing personalized, pa-
tient-centered medicine, I’m not sure that I can say the same
for those taking care of the majority of “standard asthmatics”
in this country.
Dr. Hargreave: As you say, it is a question of who is
doing the treating. But, as specialists, we need to be above
this. Why are we specialists if we can’t do this better than
everybody else? So, in terms of future guidelines, I think it
might be advantageous to have some separation between the
specialties.
Dr. Busse: The National Asthma Education and Pre-
vention Program (NAEPP) tried to tactfully address this in
the guidelines in terms of the criteria for referral to an asthma
specialist. But as discussed these past 2 days, despite these
guidelines, control is not achieved in the majority of asthma
patients, particularly those with more severe disease. Any-
thing we can do to improve it is a good idea.
Dr. Kaliner: Consider this case. A patient comes in to
my office with moderate symptoms and an forced expiratory
volume in one second (FEV1) of 45%. What do I do?
Dr. Chipps: First, see how much they reverse.
Dr. Kaliner: No reversibility; standard bronchodilator.
Dr. Chipps: Do a chest x-ray; take their smoking
history.
Dr. Kaliner: No smoking; chest x-ray is normal.
Dr. Chipps: What’s their 1-anti-tryptase level and
phenotype?
Dr. Kaliner: Normal and negative.
Dr. Oppenheimer: Does this person have normal lung
volumes or just normal spirometry?
Dr. Kaliner: Everything is commensurately reduced,
so the FEV1 is down 45%. Small airways are down, and the
patient has some shortness of breath.
Dr. Chipps: Is the ratio normal?
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Dr. Kaliner: The ratio is about 75%.
Dr. Luskin: You’re describing a patient whom we all
see, who evidences a significant dichotomy between the
physiologic, pathologic, and clinical aspects of disease. I
would treat the patient. If I’m convinced that there’s no
response to beta-agonists, I might give a short trial of
prednisone.
Dr. Kaliner: What do you tell the patient? The patient
who is, say, 40 years old says, “Am I going to die of shortness
of breath?”
Dr. Luskin: You watch, and you do what we are taught
by the guidelines to do in terms of that risk of progressive loss
of lung function that maybe we can’t do anything about.
Dr. Colice: I think this is really an important question
because within the guidelines now there are the 2 different
risk domains; and one of the risk domains is for accelerated
decline in lung function. Presumably, this patient with asthma
has had an accelerated decline in lung function over time, so
I think vigorous treatment would be required. I would put
them on prednisone for a while and probably a small particle
inhaled corticosteroid to see if I can get some small airway
improvement.
Dr. Busse: Unfortunately, I agree that we see this
patient fairly often, and it can be confusing because there is
both an obstructed and a restricted pattern (hyperinflation). I
agree with the suggested course of corticosteroids. If that
doesn’t help, then we may want to look at the differential
diagnosis of obstructive airway disease. Some studies have
indicated that, in very severe asthma, there can be airway
trapping and airway parenchymal uncoupling, with a high
buildup of residual volume leading to restrictive and obstruc-
tive components. Unfortunately, this type of patient doesn’t
always respond very well to our current therapies.
Dr. Calhoun: Another lesson from this case is that
establishing good relationships between the pulmonary and
the allergy communities is critically important.
Dr. Colice: Agreed. There are other diagnoses to con-
sider, and in this case complete pulmonary function tests and
computed tomography scans during inspiration and expira-
tion could be helpful.
Dr. Oppenheimer: Earlier, Dr. Busse mentioned refer-
ral. According to the guidelines, referral is at step 3 or step 4,
depending upon the patient’s age, yet we know that the
majority of patients and doctors in this country do not
recognize the severity of the disease. So are a lot of people
being missed because the primary care doctor isn’t acknowl-
edging that asthma is significant?
Dr. Busse: I think to a certain extent that is true.
However, hospitalization rates have dropped off, so I think
that more people are getting better care. I think the criteria we
need to look at now are how frequently patients are using
prednisone bursts. Once or twice a year is acceptable. I also
think some of the questionnaires, like the Asthma Control
Test (ACT), can be helpful. What we need to do now is to
educate the patients. A good example is cholesterol treatment.
Virtually everybody wants to know what their cholesterol is
because they know it’s a big risk factor for heart disease.
Dr. Oppenheimer: So maybe the next set of guidelines
can talk about an ACT score. I would also argue for beta-
agonist use, if we can get the pharmacists involved, and then
prednisone, which may be a better mechanism for referral.
Dr. Busse: Absolutely.
Dr. Bukstein: Let’s get back to what’s missing in the
guidelines. As mentioned earlier, I think one thing that’s
missing from asthma guidelines that is in most other chronic
disease guidelines is the role of lifestyle change.
Dr. Colice: Agreed.
Dr. Spector: Another item missing might be updated
guidance on new triggers. For example, anti-mouse antibod-
ies have now been associated with increased asthma symp-
toms, especially in the inner city. Presently, I don’t do mouse
skin tests. Should I? Is this something we should be recom-
mending in future guidelines?
Dr. Busse: I think that the specific risk factors depend
upon where you live. If you live in the inner city, there’s a
huge load of cockroach antigen, and it’s complicated by the
presence of mouse dander and fecal material. There also may
be some protectivity—the data that dogs can be protective but
not cats are interesting. Is there endotoxin or fecal material
attached to the dog, which then has an effect on the airway
response? I don’t think we have explored the environment as
much as we should. There’s also the area of microbiota and
the influence of intestinal bacteria. For example, clostridium
is associated with a shift toward TH1 and lactobacillus toward
TH2. These are some very new and exciting areas.
Dr. Spector: The other thing missing is the role of diet,
which has been talked about only peripherally. There are
some interesting data about omega-3’s and fish oil blocking
exercise-induced bronchoconstriction in various models. Vi-
tamin D and folic acid deficiency have been incriminated in
asthma. Should diet be covered better in the future? Should
we be advocating specific diets for our patients?
Dr. Calhoun: The panel attempted to be completely
evidence-based, and so the recommendations were driven
by the best evidence gathered. While there are some intrigu-
ing things about diet and other factors, it probably didn’t rise
to the level of being incorporated into the guidelines.
Dr. Luskin: We also need to understand that people
who are IgE makers are capable of making IgE to things that
we don’t usually think about—like Miller moths and Japa-
nese beetles. In terms of diet, there is intriguing information
about vitamin C, omega-3’s, and vitamin D. But are these
ready for guideline primetime? I don’t think so. The lifestyle
issues that Dr. Bukstein raised include learning how to eat
healthier and decreasing body mass; and there’s a substantial
body of evidence that these lifestyle approaches will dramat-
ically reduce the patient’s pharmaceutical burden and im-
prove quality of life.
Dr. Kaliner: What about allergy immunotherapy?
Where does that fit in?
Dr. Colice: First, let me say that I think guidelines are
great because they help us not only to crystallize our thinking
but also to point out areas where we don’t know enough about
clinical practice. That’s one aspect of guidelines that has not
been emphasized. Any time you see anything less than
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evidence level A or B, it tells you that we need more
information, more research.
With regard to immunotherapy, frankly, I do not rec-
ommend it for my patients with asthma unless they have a big
rhinitis component.
Dr. Kaliner: In our own practice, we use limited
immunotherapy for allergic rhinitis because it’s easy enough
to manage that disease unless it’s very severe, which is not
common. However, we use immunotherapy for our allergic
asthmatics at step 1. We use it as a first time indication. Our
belief, on the basis of the outcomes we see, is that in many
patients successful immunotherapy significantly reduces
(even eliminates) the asthma.
Dr. Luskin: Would you also use immunotherapy for
patients with rhinitis and bronchial hyperreactivity, but no
asthma? These people have been shown to be an at-risk
subset for developing asthma.
Dr. Kaliner: I’m not sure that I see that in practice, but
I might.
Dr. Chipps: I agree with Dr. Luskin. I think the patient
with rhinitis who is beginning to have some exercise-related
“asthma-like” symptoms is the perfect patient to treat.
Dr. Busse: In the U.S. guidelines, immunotherapy was
placed for consideration between steps 2 and 4; it’s not
advocated in the GINA guidelines. The data exist, but the
studies are not as clear as for medications. Another consid-
eration is whether parenteral immunotherapy is really what
we want to do. I’m not sure where sublingual immunotherapy
will fit, but some of the data suggest an effect on the upper
and lower airways. But doing the studies and getting type A
evidence is going to be very difficult, requiring long-term
studies.
Dr. Kaliner: This is what the guidelines are missing.
As a consequence, a sizable portion of the asthma-treating
community, without guidelines, believe that immunotherapy
has no role in managing allergic asthma. So many patients
aren’t getting allergy assessment or treatment even though
they might benefit from it. I think this is a significant hole.
Dr. Colice: I agree. There’s a lot of extraordinarily
good information in the EPR-3, but I came away without a
sense that immunotherapy was beneficial in asthma. As a
consequence, I do not prescribe it.
Dr. Luskin: So, to summarize, the NAEPP Guideline
Committee felt that it was more important to be evidence-
based than to make a statement based on incomplete evi-
dence—even if that incomplete evidence was guiding current
practice.
Dr. Busse: Yes. We were cautious.
Dr. Storms: Dr. Busse, do you think for the next
rendition of the guidelines there will be enough data from
Europe to support recommendations for sublingual or oral
dissolvable immunotherapy for asthma?
Dr. Busse: It’s a good question, and I don’t know the
answer.
Dr. Chipps: I am concerned about the seasonality of
viral infections as a risk domain that drives a lot of patients
in terms of their morbidity and that is not specifically dis-
cussed with regard to not stepping down treatment.
Dr. Busse: As noted earlier, stepping down is not
addressed very well. In this regard, I think an area that is
particularly intriguing is the “September epidemic” in chil-
dren. During the summer months, many children stop their
medications because they are not in school, and they some-
times feel better. Then they go back to school and “boom.”
We thought it was probably due to rhinovirus, but in a study
we did one of the major risk factors was cockroach sensitiv-
ity. That raises the question again about the interplay between
environmental factors, viruses, and antigens. A major risk
factor for having an asthma exacerbation is being allergic,
and how this interplays with viral infection is very intriguing.
Dr. Hargreave: I agree that it needs to be taken into
consideration. You showed that virus infection increased the
late response to allergen inhalation.
Dr. Busse: Yes, almost 15 years ago. The interaction
with virus changed things a lot.
Dr. Hargreave: Anecdotally, we’ve seen that if a
patient has eosinophilia and gets an infection on top of it, that
patient is much more likely to have symptoms.
Dr. Busse: We really haven’t talked about the suscep-
tibility to events that are occurring because these are not
things that we measure. I think we need to look at different
outcomes depending upon the stimulus. Until we do that, it’s
not easy to show effectiveness, remembering that effective-
ness is not just an improvement in FEV1.
Dr. Calhoun: So I’d like to bring this back to a
question that was raised at the very beginning of the sympo-
sium, in the opening debate between Dr. Busse and Dr.
Bousquet. Several folks articulated that we really need to
have a universal guideline for asthma. I’d like a little discus-
sion on that point, recognizing that there are cultural differ-
ences. For example, in Japan, the use of inhaled drugs is not
very well accepted. There are also important differences in
the regulatory landscapes between countries. So, is the con-
cept of a universal guideline for asthma something that’s
interesting but unachievable or is there a way forward that
will accommodate some of these regulatory and cultural
differences?
Dr. Busse: If you look at guidelines from different
countries, there are many components that are in agreement:
the characteristics of the disease and the steps of severity.
Then the countries go to their local environments as to how
to do things.
Dr. Colice: It’s an interesting question. You know, of
course, in chronic obstructive pulmonary disease (COPD)
there’s a much clearer agreement on international guidelines
with the Global initiative for chronic Obstructive Lung Dis-
ease (GOLD) approach, so I think there is a possibility of
achieving that. But I think we are a lot better off than we were
10 years ago. There’s a lot more clarity as to where we should
be going.
Dr. Luskin: That brings up another issue, which is
what needs to happen to optimize the effectiveness of the
guidelines and how to put them into operation. They are a
fantastic reference, but in practical terms not particularly
useful, especially for the group that sees the most asthmatic
patients. The Guideline Implementation Committee sug-
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gested 22 key messages and then 6 “really” key messages. It
might be worthwhile to look at what National Committee for
Quality Assurance (NCQA) and the American Medical As-
sociation (AMA) conjoint panel suggested as useful for
judging quality in asthma care. They suggested the following:
(1) there needs to be assessment of control at every visit, and
the ACT is an easy way of doing that; (2) there needs to be
assessment of risk at every visit; (3) every patient should get
a written action plan; (4) appropriate pharmacotherapy should
be controller medication for persistent asthma, and they favor
looking at a controller-to-reliever ratio to predict patients at high
risk for exacerbations; (5) smoking cessation is critical; (6)
follow-up after an urgent visit should happen within 1 to 2
weeks, and inhaled corticosteroid should be prescribed at dis-
charge from urgent care. According to the NCQA and the AMA,
those are what would most likely help people implement the
guidelines.
Dr. Colice: I would implement the guidelines in 2
different ways. First, we should implement in a uniform way
the grade A evidence. Evidence below that should be prior-
itized for research, which is where the NHLBI comes in.
Dr. Hargreave: In summary, asthma is a disorder defined
by clinical, physiological, and/or pathologic criteria. But basi-
cally we see asthma as variable airflow obstruction. That’s how
we make the diagnosis. That’s what we’re talking about when
we talk about asthma. So the guidelines definitions are descrip-
tive. There’s no primary defining characteristic. They don’t tell
us that when we talk about asthma, we’re talking about airflow
limitation, which varies over short periods of time; they don’t
really tell us how to make the diagnosis, though there is expla-
nation for how that can be done. However, they imply that there
are several characteristics that you have to have to have asthma;
but with all this heterogeneity going on, that isn’t the case. So we
are confused. We’ve talked about heterogeneity. There’s heter-
ogeneity among the components in people with airway disease,
so they can have 1 or several of these different abnormal
characteristics.
An editorial in the Lancet about 2 years ago suggested that
we should abandon asthma as a disease concept. I agree with
that. Continue to use the term as an abnormality of function and
exactly describe each subject using measurements. We need to
assess what the different things are that are contributing to each
patient’s symptoms, and then we treat them. This is how we can
personalize treatment; and that’s what we’ve been talking about,
in fact, throughout this meeting.
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